Monoclonal antibodies combined to chemotherapy for the treatment of patients with lymphoma

Blood Reviews

Volumn 17, Issue 1, 2003, Pages 25-31

  Coiffier, Bertrand ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

Alemtuzumab; Ibritumomoab tiuxetan; Lymphoma; Monoclonal antibodies; Rituximab; Tositumomab

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; DOXORUBICIN; EPRATUZUMAB; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; METHOTREXATE DERIVATIVE; MONOCLONAL ANTIBODY; PREDNISONE; RITUXIMAB; TIUXETAN; TOSITUMOMAB I 131; VINCRISTINE;

ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE ACTIVATION; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL INTERACTION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; FOLLICULAR LYMPHOMA; FOLLOW UP; HEMATOPOIETIC STEM CELL; HUMAN; INTERMETHOD COMPARISON; LIVER TOXICITY; LUNG TOXICITY; LYMPHOMA; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; MONOTHERAPY; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; VOMITING;

EID: 0037362016     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(02)00059-0     Document Type: Article

References (47)

1. Grillo-Lopez AJ. White CA, Varns C et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 1999; 26: 66-73.
2. Grossbard ML, Fidias P, Kinsella J et al. Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma. Brit J Haematol 1998; 102: 509-515.
3. Kaminski MS, Zasadny KR, Francis IR et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996; 14: 1974-1981.
4. Witzig TE, White CA, Wiseman GA et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3793-3803.
5. Maloney DG, Liles TM, Czerwinski DK et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457-2466.
6. Maloney DG, Grillolopez AJ, Bodkin DJ et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 3266-3274.
7. Foran JM, Rohatiner AZS, Coiffier B et al. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 1999; 17: 546-553.
8. Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma. A multicenter phase II study. Blood 1998; 92: 1927-1932.
9. Demidem A, Lam T, Alas S et al. Chimeric anti-CD20 (Idec-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12: 177-186.
10. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998; 91: 1644-1652.
11. Shan DM, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000; 48: 673-683.
12. Ghetie MA, Bright H, Vitetta ES. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 2001; 97: 1392-1398.
13. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/ paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001; 61: 5137-5144.
14. Kreitman RJ, Wilson WH, Bergeron K et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001; 345: 241-247.
15. Dearden CE, Matutes E, Cazin B et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-IH. Blood 2001; 98: 1721-1726.
16. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
17. Kaminski MS, Zelenetz AD, Press OW et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001; 19: 3918-3928.
18. Gordon LI, Witzig TE, Emmanouilides CE, et al. 90Y ibritumomab (Zevalin) in aggressive non-Hodgkin's lymphoma: analysis of response and toxicity. Proc ASCO 2002; 21: 266a.
19. Foran JM, Rohatiner AZS, Cunningham D et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18: 317-324.
20. Foran JM, Cunningham D, Coiffier B et al. Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol 2000; 11: 117-121.
21. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a Working Formulation for Clinical Usage. Cancer 1982; 49: 2112-2135.
22. Pan D, Moskowitz CH, Zelenetz AD et al. Clinical outcomes of patients treated with rituximab for relapsed or refractory aggressive non-Hodgkin's lymphoma in the post-transplant setting. Blood 2000; 96.
23. Lundin J, Kimby E, Bjorkholm M et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-IH) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100: 768-773.
24. Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (Campath-IH) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554-3561.
25. Uppenkamp M, Engert A, Diehl V et al. Monoclonal antibody therapy with CAMPATH-IH in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study. Ann Hematol 2002; 81: 26-32.
26. Keating MJ, Cazin B, Coutre S et al. Campath-IH treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 2002; 20: 205-213.
27. Leonard JP, Coleman M, Matthews JC, et al. Epratuzumab (anti-CD22) and rituximab (anti-CD20) combination immunotherapy for non-Hodgkin's lymphoma: preliminary response data. Proc ASCO 2002; 21: 266a.
28. Witzig TE, Flinn IW, Gordon LI et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3262-3269.
29. Witzig TE, White CA, Wiseman GA et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3793-3803.
30. Vose JM, Wahl RL, Saleh M et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000; 18: 1316-1323.
31. Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453-2463.
32. Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268-276.
33. Czuczman MS, Fallon A, Mohr A et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 2002; 29: 36-40.
34. Howard OM, Gribben JG, Neuberg DS et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20: 1288-1294.
35. Romaguera JE, Dang NH, Hagemeister FB et al. Preliminary report of rituximab with intensive chemotherapy for untreated aggressive mantle cell lymphoma (MCL). Blood 2000; 96: 733a.
36. Vose JM, Link BK, Grossbard ML et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001; 19: 389-397.
37. Kewalramani T, Zelenetz A, Bertino J, et al. Rituximab significantly increases the complete response rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy. Blood 2001.
38. Coiffier B, Lepage E, Brière J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
39. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-994.
40. Hiddemann W, Forstpointner R, Fiedler F, et al. The addition of rituximab to combination chemotherapy with fludarabine, cyclophosphamide, mitoxantrone (FCM) results in a significant increase of overall response as compared to FCM alone in patients with relapsed or refractory follicular (FCL) and mantel cell lymphomas (MCL). Results of a prospective randomized comparison of the German low grade study group (GLSG). Blood 2001.
41. Press OW, Eary JF, Gooley T et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000; 96: 2934-2942.
42. Ghielmini M, Schmite SFH, Cogliatti SB et al. Maintenance treatment with 2-montly rituximab after standard weekly × 4 rituximab induction significantly improves efent-free survival in patients with follicular lymphoma. Ann Oncol 2002; 13(Suppl 2): 38.
43. Leonard JP, Link BK. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and HuID10 (apolizumab). Semin Oncol 2002; 29: 81-86.
44. Gordon LI, Witzig TE, Wiseman GA et al. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. Semin Oncol 2002; 29: 87-92.
45. Kaminski MS, Estes J, Zasadny KR et al. Radioimmunotherapy with iodine 1-131 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96: 1259-1266.
46. Olsen E, Duvic M, Frankel A et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19: 376-388.
47. Coiffier B. Diffuse large cell lymphoma. Curr Opin Oncol 2001; 13: 325-334.